WO2003013438A2 - Nutrient therapy for immuno-compromised patients - Google Patents

Nutrient therapy for immuno-compromised patients Download PDF

Info

Publication number
WO2003013438A2
WO2003013438A2 PCT/US2002/025358 US0225358W WO03013438A2 WO 2003013438 A2 WO2003013438 A2 WO 2003013438A2 US 0225358 W US0225358 W US 0225358W WO 03013438 A2 WO03013438 A2 WO 03013438A2
Authority
WO
WIPO (PCT)
Prior art keywords
sod
nutritional supplement
component
group
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/025358
Other languages
English (en)
French (fr)
Other versions
WO2003013438A3 (en
Inventor
Carl Germano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Biotechnologies Inc
Original Assignee
Millennium Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Biotechnologies Inc filed Critical Millennium Biotechnologies Inc
Priority to CA002457624A priority Critical patent/CA2457624A1/en
Priority to EA200400291A priority patent/EA006439B1/ru
Priority to EP02759316A priority patent/EP1432436A4/en
Priority to APAP/P/2004/002994A priority patent/AP2004002994A0/en
Priority to JP2003518452A priority patent/JP2005501061A/ja
Publication of WO2003013438A2 publication Critical patent/WO2003013438A2/en
Publication of WO2003013438A3 publication Critical patent/WO2003013438A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • HIV HIV induced Acquired Immune Deficiency Syndrome
  • antiretroviral drugs such as AZT and other viral suppressive compounds
  • AZT antiretroviral drugs
  • viral suppressive compounds include AZT and other viral suppressive compounds.
  • most of these drugs to be effective have to be taken in combination with complicated regimes that need to be followed meticulously and indefinitely.
  • the toxic nature of these drugs leads to further decreases in host defense, energy production and increases in oxidative stress furthering the development of the disease.
  • These drugs are expensive and not affordable by many if not most HIV infected persons.
  • composition comprises in combination:
  • Carnitine which regulates the metabolism and function of peripheral nerves and mitochondrial DNA synthesis could contribute to the neurotoxicity of certain medications used to treat the disease as well as apoptosis and other significant symptoms. The depletion also is attributed to the clinical symptoms of myalgia and muscle weakness associated with the disease. Because Carnitine status is an important contributing factor to immune function in patients with AIDS, L-carnitine supplementation could have a role as a complimentary therapy for HIV infected individuals.
  • branched-chain amino acids may help restore muscle mass following surgery, an injury, or trauma. They also help in people who have liver disease. A general deficiency of protein in the diet can cause a loss of stamina, lowered resistance to infection, slow healing of wounds, weakness, and depression.
  • a conventional blend of vitamins and minerals can be incorporated.
  • Other conventional ingredients to nutrient drinks may be added.
  • Beta Glucans 50 mg to 500 mg 100 mg to 300 mg Fruit Polyphenols 25 mg to 500 mg 25 mg to 100 mg
  • VALINE L-VALINE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
PCT/US2002/025358 2001-08-10 2002-08-09 Nutrient therapy for immuno-compromised patients Ceased WO2003013438A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002457624A CA2457624A1 (en) 2001-08-10 2002-08-09 Nutrient therapy for immuno-compromised patients
EA200400291A EA006439B1 (ru) 2001-08-10 2002-08-09 Пероральная пищевая добавка для лечения хронических изнуряющих заболеваний
EP02759316A EP1432436A4 (en) 2001-08-10 2002-08-09 NUTRIENT THERAPY FOR PATIENTS WITH AN IMMUNE SYSTEM COMPROMISED
APAP/P/2004/002994A AP2004002994A0 (en) 2001-08-10 2002-08-09 Nutrient therapy for immuno-compromised patients
JP2003518452A JP2005501061A (ja) 2001-08-10 2002-08-09 免疫機能損傷患者の為の栄養療法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/927,174 US6503506B1 (en) 2001-08-10 2001-08-10 Nutrient therapy for immuno-compromised patients
US09/927,174 2001-08-10

Publications (2)

Publication Number Publication Date
WO2003013438A2 true WO2003013438A2 (en) 2003-02-20
WO2003013438A3 WO2003013438A3 (en) 2003-06-19

Family

ID=25454328

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/025358 Ceased WO2003013438A2 (en) 2001-08-10 2002-08-09 Nutrient therapy for immuno-compromised patients

Country Status (9)

Country Link
US (1) US6503506B1 (enExample)
EP (1) EP1432436A4 (enExample)
JP (1) JP2005501061A (enExample)
CN (1) CN1568196A (enExample)
AP (1) AP2004002994A0 (enExample)
CA (1) CA2457624A1 (enExample)
EA (1) EA006439B1 (enExample)
OA (1) OA12649A (enExample)
WO (1) WO2003013438A2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1600061A1 (en) * 2004-05-25 2005-11-30 Cognis IP Management GmbH Oral and/or topical compositions
JP2005336176A (ja) * 2004-04-28 2005-12-08 Tanabe Seiyaku Co Ltd 肉体疲労改善剤
JP2006111566A (ja) * 2004-10-14 2006-04-27 Taisho Pharmaceut Co Ltd メチオニン配合内服液剤
JP2007508343A (ja) * 2003-10-16 2007-04-05 ネステク ソシエテ アノニム 化学療法又は放射線療法の副作用に対する栄養組成物
WO2007099151A1 (en) * 2006-03-01 2007-09-07 Etren Methods and agents for reducing oxidative stress
JPWO2006003927A1 (ja) * 2004-06-30 2008-07-31 敦生 関山 非炎症性ストレス応答の指標剤およびその利用
US11903922B2 (en) 2010-12-23 2024-02-20 Amazentis Sa Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6616942B1 (en) 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
FR2822704B1 (fr) * 2001-03-29 2005-02-18 Chiesi Sa Sels de cetoacides et d'acides amines gastroresistants et leur utilisation pour la preparation de medicaments
US6503506B1 (en) * 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients
US20080089877A1 (en) * 2003-08-14 2008-04-17 Udell Ronald G Super Absorption Coenzyme Q10
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
US8105583B2 (en) * 2003-09-29 2012-01-31 Soft Gel Technologies, Inc. Solubilized CoQ-10
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
ITTO20030789A1 (it) 2003-10-07 2005-04-08 Professional Dietetics Srl Composizione a base di amino acidi per il trattamento
CN110522717A (zh) 2004-01-22 2019-12-03 迈阿密大学 局部辅酶q10制剂及其使用方法
CN1917779B (zh) * 2004-01-28 2010-06-16 雀巢技术公司 用于改善皮肤状况和防止皮肤病的营养组合物
US20050209170A1 (en) * 2004-03-18 2005-09-22 Takemoto Arnold C Breast health preparations
CA2559938A1 (en) * 2004-03-17 2005-09-29 Arnold C. Takemoto Tissue detoxification and health supplements and methods of making and using them
US20050265990A1 (en) * 2004-06-01 2005-12-01 Shawn Talbott Treatments and nutritional supplements for assisting post-exercise recovery
KR100584891B1 (ko) 2004-08-13 2006-05-30 (주)씨스팜 경구용 슈퍼옥사이드 디스뮤타제 제제인, 캔털루프 멜론추출물과 글리아딘 결합물을 숙취해소에 사용하는 방법
US7284385B2 (en) * 2004-09-16 2007-10-23 Hess Spencer W Pre-dried air reactivation for diesel fuel heated dessicant reactivator
US20060147550A1 (en) * 2004-12-30 2006-07-06 Gorsek Wayne F Immune system enhancement and stimulation formulation
US20070114476A1 (en) * 2005-11-04 2007-05-24 Williams Christopher P Low radiocarbon nucleotide and amino acid dietary supplements
CA2631647A1 (en) * 2005-11-30 2007-06-07 Nestec S.A. Use of branched-chain amino acids for the treatment of muscle loss
WO2007077995A1 (ja) * 2006-01-05 2007-07-12 Kyowa Hakko Kogyo Co., Ltd. 筋肉増量剤
WO2007105024A1 (en) * 2006-03-15 2007-09-20 Isocell Pharma S.A. Pharmaceutical compositions comprising sods and prolamine based peptide fragments
FR2899065B1 (fr) * 2006-03-29 2008-07-18 Alain Dreyer Brevets Et Dev So Sod micro encapsulee et adsorbee sur support mineral et vegetal destinee a l'alimentation animale
DE102006046960A1 (de) * 2006-10-04 2008-04-10 Euro Allianz Pharma Gmbh Gesundheitsfördernde Nahrungsmittelzusammensetzung
US20080119386A1 (en) * 2006-11-22 2008-05-22 Carl Germano Nutritional formula for athletes' recovery
US8343541B2 (en) * 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
EP2158462A4 (en) 2007-05-03 2010-05-05 Radiocarb Genetics Inc FOOD SUPPLEMENTS WITH LITTLE RADIO CARBON AND MANUFACTURING METHOD THEREFOR
EP2205250B1 (en) * 2007-09-27 2016-05-04 Biothera, Inc. ß-GLUCAN TREATMENT OF UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING
WO2009099444A1 (en) * 2008-02-08 2009-08-13 Millennium Biotechnologies, Inc. Nutritional formula for athletes' recovery
EP2271325A4 (en) 2008-04-11 2011-11-09 Cytotech Labs Llc METHODS AND USE OF INDUCING APOPTOSIS IN CANCER CELLS
WO2010053854A1 (en) * 2008-11-06 2010-05-14 Altman Enterprises Llc Medication and treatment for disease
US20110020312A1 (en) 2009-05-11 2011-01-27 Niven Rajin Narain Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
EP2311449A1 (de) * 2009-10-14 2011-04-20 NÖM Aktiengesellschaft Oral verabreichbare nahrungsergänzende Zusammensetzung enthaltend Carnitin
WO2012097061A1 (en) * 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for improving skeletal muscle protein metabolism
WO2012099980A2 (en) * 2011-01-18 2012-07-26 Equine Nutriceuticals, Llc Equine nutritional supplement
US20120269867A1 (en) 2011-04-04 2012-10-25 Jimenez Joaquin J Methods of treating central nervous system tumors
EA032775B1 (ru) 2013-04-08 2019-07-31 Берг Ллк Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
US9901542B2 (en) 2013-09-04 2018-02-27 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme Q10
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
CN105709212A (zh) * 2016-01-29 2016-06-29 周瑞华 一种免疫平衡调节剂及其制备方法和应用
RU2656544C1 (ru) * 2017-07-07 2018-06-05 Общество с ограниченной ответственностью "Академия-Т" Функциональный продукт питания для коррекции психофизиологического состояния и нейромышечной передачи у спортсменов
CA3109188A1 (en) * 2018-08-10 2020-02-13 Maine Natural Health Company, Inc. Comestible compositions for promoting atp synthesis
CN110664824B (zh) * 2019-08-09 2021-01-01 北京佳博泰和健康科技有限公司 一种营养支持剂及其制备方法和用途
CN111820330A (zh) * 2020-07-17 2020-10-27 禹城保立康生物饲料有限公司 一种提高哺乳仔猪发育的母猪饲料

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5456924A (en) * 1988-12-23 1995-10-10 Immunotec Research Corporation Ltd. Method of treatment of HIV-seropositive individuals with dietary whey proteins
IT1258491B (it) * 1992-09-24 1996-02-26 Sigma Tau Ind Farmaceuti Impiego di l-carnitina e acil l-carnitine nel trattamento di pazienti affetti da aids e sindromi correlate e di pazienti asintomatici hiv- sieropositivi.
FR2729296B1 (fr) 1995-01-12 1997-03-28 Europlanaire Compositions pharmaceutiques comprenant une superoxyde dismutase
US5817329A (en) * 1997-02-28 1998-10-06 Gardiner; Paul T. Nutritional supplement for increased muscle size and strength for body builders
US6503506B1 (en) * 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007508343A (ja) * 2003-10-16 2007-04-05 ネステク ソシエテ アノニム 化学療法又は放射線療法の副作用に対する栄養組成物
JP2005336176A (ja) * 2004-04-28 2005-12-08 Tanabe Seiyaku Co Ltd 肉体疲労改善剤
EP1600061A1 (en) * 2004-05-25 2005-11-30 Cognis IP Management GmbH Oral and/or topical compositions
WO2005115170A1 (en) * 2004-05-25 2005-12-08 Cognis Ip Management Gmbh Oral and /or topical compositions
JPWO2006003927A1 (ja) * 2004-06-30 2008-07-31 敦生 関山 非炎症性ストレス応答の指標剤およびその利用
JP5069000B2 (ja) * 2004-06-30 2012-11-07 敦生 関山 非炎症性ストレス応答の指標剤およびその利用
JP2006111566A (ja) * 2004-10-14 2006-04-27 Taisho Pharmaceut Co Ltd メチオニン配合内服液剤
WO2007099151A1 (en) * 2006-03-01 2007-09-07 Etren Methods and agents for reducing oxidative stress
US11903922B2 (en) 2010-12-23 2024-02-20 Amazentis Sa Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
US12036205B2 (en) 2010-12-23 2024-07-16 Amazentis Sa Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
US12310943B2 (en) 2010-12-23 2025-05-27 Amazentis Sa Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

Also Published As

Publication number Publication date
CA2457624A1 (en) 2003-02-20
WO2003013438A3 (en) 2003-06-19
OA12649A (en) 2006-06-16
AP2004002994A0 (en) 2004-03-31
JP2005501061A (ja) 2005-01-13
EP1432436A2 (en) 2004-06-30
EA006439B1 (ru) 2005-12-29
US6503506B1 (en) 2003-01-07
EP1432436A4 (en) 2005-02-09
CN1568196A (zh) 2005-01-19
EA200400291A1 (ru) 2004-08-26

Similar Documents

Publication Publication Date Title
US6503506B1 (en) Nutrient therapy for immuno-compromised patients
EP1439831B1 (en) Pharmaco-dietary preparation having a nutrition-supplementing and nutrition-enhancing effect
EP1455603B1 (en) Stimulation of in vivo production of proteins with formulation comprising leucine
USRE40849E1 (en) Method of treatment of glutathione deficient mammals
US5230902A (en) Undenatured whey protein concentrate to improve active systemic humoral immune response
US9956255B1 (en) Method to reduce body weight, fat accumulation and adipocyte size using Parabacteroides goldsteinii
US20200155589A1 (en) Composition For Enchanced Recovery After Surgery (ERAS)
EP1748705B1 (en) Use of beta-cryptoxanthin
WO2011096413A1 (ja) 運動機能改善剤
ES2743955T3 (es) Composiciones que comprenden cinamaldehído y zinc y métodos para utilizar tales composiciones
JP2007523157A (ja) 風邪予防用組成物
US20120178799A1 (en) Energy beverage with creatine and caffeine combination
WO2010107307A1 (en) Kit of parts comprising l-glutamine and egcg
JP5394644B2 (ja) アスペルロシドまたはその類縁体を含む筋肉増強剤
AU2002324659A1 (en) Nutrient therapy for immuno-compromised patients
CN106036387A (zh) 超级藜麦儿童生长营养包
CA2507887A1 (en) Nucleotide based medicament and method of use for treatment of conditions in humans
HK1073261A (en) Nutrient therapy for immuno-compromised patients
Cribb Whey proteins and immunity
WO2025213012A1 (en) Gummy nutritional product and method
EP1534087A1 (en) Low-energy-diet
HK1065447B (en) Stimulation of in vivo production of proteins with formulation comprising leucine
JPS60237024A (ja) 肥満抑制組成物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EE ES FI GB GD GE GH GM HU ID IL IN IS JP KE KG KP KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ PL PT RO RU SD SG SI SK SL TJ TM TR TT TZ UA UG VN YU ZA

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003518452

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2457624

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002324659

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002759316

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200400291

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: AP/P/2004/002994

Country of ref document: AP

WWE Wipo information: entry into national phase

Ref document number: 20028199790

Country of ref document: CN

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002759316

Country of ref document: EP